What “compliance” and “dropout” usually mean for Orladeyo (berotralstat)
For Orladeyo, “compliance” typically refers to whether patients take berotralstat exactly as prescribed (most importantly, keeping to the daily dosing schedule and not missing doses). “Dropout” usually means patients stop taking the medicine before the study or follow-up period ends, or discontinue treatment in real-world care.
How is Orladeyo dosing meant to affect adherence?
Orladeyo (berotralstat) is taken orally on a fixed schedule rather than as needed. That design generally pushes adherence to be about daily consistency: if someone misses doses or stops because of tolerance, cost, or perceived lack of benefit, it can reduce the chance of staying on therapy.
What are the main reasons people discontinue preventive therapies like Orladeyo?
Across studies and real-world settings, discontinuation often comes from side effects, inadequate perceived benefit, difficulty sticking to daily treatment, insurance/cost barriers, or practical issues (pharmacy access, refills, or follow-up). For Orladeyo specifically, the most actionable question is usually whether a patient’s experience (side effects, effectiveness during attacks, or lab/monitoring issues) is tolerable enough to keep going.
What side effects are most likely to drive dropout?
Side effects are a common reason for early stopping with oral preventive medicines. If you’re tracking dropout, the practical approach is to look for patterns like:
- GI symptoms soon after starting or dose changes
- Reactions that persist despite continued use
- Symptoms that improve but then recur with missed doses or restarting
If you share which side effects you mean (or your age/HAE history), I can help interpret how those factors typically affect continuation.
How to measure adherence and dropout for Orladeyo in a clinic or study
To talk about Orladeyo compliance and dropout in a concrete way, people usually look at:
- Missed-dose frequency (how often refills lapse or doses are skipped)
- Treatment persistence (days on therapy, time-to-discontinuation)
- Reasons for discontinuation (side effects, lack of efficacy, administrative/financial issues)
- Proportion staying on treatment through follow-up time
If you’re asking about a specific Orladeyo trial: which ones?
Different Orladeyo studies report discontinuation and adherence differently (and may separate reasons for stopping). If you tell me the study name or year (or the clinical trial number), I can summarize the dropout rates and the reported adherence/compliance findings from that exact dataset.
Can switching timing or managing side effects improve staying on Orladeyo?
Often, adherence improves when a clinician helps with:
- Taking the medicine in a consistent routine
- Managing expected early side effects (when appropriate)
- Reviewing whether the prevention targets (attack reduction and severity) are being met
This matters because dropout can happen when patients do not see enough benefit quickly enough or if side effects feel disproportionate.
Need the exact dropout/compliance numbers?
If you want the actual rates (percent who discontinued, and why), I’ll need one of the following:
- the Orladeyo study/trial name or NCT number, or
- whether you mean real-world persistence (claims/EHR) vs. clinical trial dropout.
Once you provide that, I can pull together the specific compliance and dropout figures.
Sources
No sources were provided in the prompt.